Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs Best Available Therapy in Steroid-Refractory Chronic Graft-versus-Host Disease
2016-004432-38Phase 3Unknown
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Novartis. Primary endpoint: Overall response rate at Cycle 7 Day 1. Status: unknown.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2016-004432-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004432-38.